Immunotherapy of human immunodeficiency virus infection
Identifieur interne : 001375 ( Istex/Corpus ); précédent : 001374; suivant : 001376Immunotherapy of human immunodeficiency virus infection
Auteurs : John W. HaddenSource :
- Trends in Pharmacological Sciences [ 0165-6147 ] ; 1991.
English descriptors
- Teeft :
- Antiviral, Antiviral therapy, Bone marrow transplantation, Companion viruses, Hadden, Immune response, Immunorestorative therapy, Immunotherapy, Intravenous immunoglobulin therapy, Lymphocyte, Lymphocyte counts, Multicenter, Multicenter trial, Neutralizing antibody, Opportunistic infections, Peptide, Pituitary hormones, Preliminary data, Preliminary results, Symptomatic patients, Thymic, Thymus, Tips march, Vaccine development, Viral, Viral recovery, Viral replication, Zidovudine, Zidovudine treatment.
Abstract
Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.
Url:
DOI: 10.1016/0165-6147(91)90517-V
Links to Exploration step
ISTEX:F55000397C57F0F1E72CAEE40B64AC817587F394Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immunotherapy of human immunodeficiency virus infection</title><author><name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name><affiliation><mods:affiliation>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F55000397C57F0F1E72CAEE40B64AC817587F394</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0165-6147(91)90517-V</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001375</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001375</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immunotherapy of human immunodeficiency virus infection</title><author><name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name><affiliation><mods:affiliation>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Trends in Pharmacological Sciences</title><title level="j" type="abbrev">TIPS</title><idno type="ISSN">0165-6147</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">C</biblScope><biblScope unit="page" from="107">107</biblScope><biblScope unit="page" to="111">111</biblScope></imprint><idno type="ISSN">0165-6147</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0165-6147</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antiviral</term><term>Antiviral therapy</term><term>Bone marrow transplantation</term><term>Companion viruses</term><term>Hadden</term><term>Immune response</term><term>Immunorestorative therapy</term><term>Immunotherapy</term><term>Intravenous immunoglobulin therapy</term><term>Lymphocyte</term><term>Lymphocyte counts</term><term>Multicenter</term><term>Multicenter trial</term><term>Neutralizing antibody</term><term>Opportunistic infections</term><term>Peptide</term><term>Pituitary hormones</term><term>Preliminary data</term><term>Preliminary results</term><term>Symptomatic patients</term><term>Thymic</term><term>Thymus</term><term>Tips march</term><term>Vaccine development</term><term>Viral</term><term>Viral recovery</term><term>Viral replication</term><term>Zidovudine</term><term>Zidovudine treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>lymphocyte</json:string><json:string>antiviral</json:string><json:string>zidovudine</json:string><json:string>immunotherapy</json:string><json:string>thymus</json:string><json:string>multicenter</json:string><json:string>antiviral therapy</json:string><json:string>hadden</json:string><json:string>viral</json:string><json:string>thymic</json:string><json:string>peptide</json:string><json:string>tips march</json:string><json:string>preliminary data</json:string><json:string>lymphocyte counts</json:string><json:string>immunorestorative therapy</json:string><json:string>zidovudine treatment</json:string><json:string>viral replication</json:string><json:string>immune response</json:string><json:string>neutralizing antibody</json:string><json:string>bone marrow transplantation</json:string><json:string>pituitary hormones</json:string><json:string>preliminary results</json:string><json:string>intravenous immunoglobulin therapy</json:string><json:string>multicenter trial</json:string><json:string>viral recovery</json:string><json:string>symptomatic patients</json:string><json:string>opportunistic infections</json:string><json:string>vaccine development</json:string><json:string>companion viruses</json:string></teeft></keywords><author><json:item><name>John W. Hadden</name><affiliations><json:string>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612, USA</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-LFNR42MJ-0</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Review article</json:string></originalGenre><abstract>Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.</abstract><qualityIndicators><score>6.618</score><pdfWordCount>3334</pdfWordCount><pdfCharCount>23142</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>519 x 756 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>107</abstractWordCount><abstractCharCount>816</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Immunotherapy of human immunodeficiency virus infection</title><pmid><json:string>2053187</json:string></pmid><pii><json:string>0165-6147(91)90517-V</json:string></pii><genre><json:string>review-article</json:string></genre><serie><title>No. 1</title><language><json:string>unknown</json:string></language></serie><host><title>Trends in Pharmacological Sciences</title><language><json:string>unknown</json:string></language><publicationDate>1991</publicationDate><issn><json:string>0165-6147</json:string></issn><pii><json:string>S0165-6147(00)X0189-7</json:string></pii><volume>12</volume><pages><first>107</first><last>111</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1991</json:string></date><geogName></geogName><orgName><json:string>Biochem</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Bernard Waeber</json:string><json:string>Michel Burnier</json:string><json:string>Philippe Walker</json:string><json:string>J. Cell</json:string><json:string>NY Acad</json:string><json:string>Raven Press</json:string><json:string>N. Egl</json:string><json:string>Eric Grouzmann</json:string><json:string>E. Crownm</json:string><json:string>N. EqI</json:string><json:string>John Hadden</json:string><json:string>J. Clbr</json:string><json:string>O.W. Asympt</json:string><json:string>M. Goof</json:string><json:string>J. Lab</json:string><json:string>N. Et</json:string></persName><placeName><json:string>Toxicity</json:string><json:string>Europe</json:string><json:string>San Francisco</json:string><json:string>York</json:string><json:string>Italy</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Schwartz et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-LFNR42MJ-0</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Toxicology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - genetique medicale</json:string></inist></categories><publicationDate>1991</publicationDate><copyrightDate>1991</copyrightDate><doi><json:string>10.1016/0165-6147(91)90517-V</json:string></doi><id>F55000397C57F0F1E72CAEE40B64AC817587F394</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Immunotherapy of human immunodeficiency virus infection</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1991</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: TIPS review</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Immunotherapy of human immunodeficiency virus infection</title><author xml:id="author-0000"><persName><forename type="first">John W.</forename><surname>Hadden</surname></persName><affiliation>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612, USA</affiliation></author><idno type="istex">F55000397C57F0F1E72CAEE40B64AC817587F394</idno><idno type="ark">ark:/67375/6H6-LFNR42MJ-0</idno><idno type="DOI">10.1016/0165-6147(91)90517-V</idno><idno type="PII">0165-6147(91)90517-V</idno></analytic><monogr><title level="j">Trends in Pharmacological Sciences</title><title level="j" type="abbrev">TIPS</title><idno type="pISSN">0165-6147</idno><idno type="PII">S0165-6147(00)X0189-7</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991"></date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">C</biblScope><biblScope unit="page" from="107">107</biblScope><biblScope unit="page" to="111">111</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1991</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.</p></abstract></profileDesc><revisionDesc><change when="1991">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="rev"><item-info><jid>TIPS</jid><aid>9190517V</aid><ce:pii>0165-6147(91)90517-V</ce:pii><ce:doi>10.1016/0165-6147(91)90517-V</ce:doi><ce:copyright type="unknown" year="1991"></ce:copyright></item-info><head><ce:dochead><ce:textfn>TIPS review</ce:textfn></ce:dochead><ce:title>Immunotherapy of human immunodeficiency virus infection</ce:title><ce:author-group><ce:author><ce:given-name>John W.</ce:given-name><ce:surname>Hadden</ce:surname></ce:author><ce:affiliation><ce:textfn>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612, USA</ce:textfn></ce:affiliation></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, <ce:italic>John Hadden</ce:italic> argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Immunotherapy of human immunodeficiency virus infection</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Immunotherapy of human immunodeficiency virus infection</title></titleInfo><name type="personal"><namePart type="given">John W.</namePart><namePart type="family">Hadden</namePart><affiliation>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="Review article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.</abstract><note type="content">Section title: TIPS review</note><relatedItem type="host"><titleInfo><title>Trends in Pharmacological Sciences</title></titleInfo><titleInfo type="abbreviated"><title>TIPS</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued></originInfo><identifier type="ISSN">0165-6147</identifier><identifier type="PII">S0165-6147(00)X0189-7</identifier><part><date>1991</date><detail type="volume"><number>12</number><caption>vol.</caption></detail><detail type="supplement"><number>C</number><caption>Suppl.</caption></detail><extent unit="issue-pages"><start>1</start><end>474</end></extent><extent unit="pages"><start>107</start><end>111</end></extent></part></relatedItem><identifier type="istex">F55000397C57F0F1E72CAEE40B64AC817587F394</identifier><identifier type="ark">ark:/67375/6H6-LFNR42MJ-0</identifier><identifier type="DOI">10.1016/0165-6147(91)90517-V</identifier><identifier type="PII">0165-6147(91)90517-V</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001375 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001375 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F55000397C57F0F1E72CAEE40B64AC817587F394
|texte= Immunotherapy of human immunodeficiency virus infection
}}
| This area was generated with Dilib version V0.6.33. |  |